Table 2 Therapeutic interventions during ICU stay among both groups.
Medication administered | All patients N (%) | Tocilizumab N (%) | Non-tocilizumab N (%) | p-value |
|---|---|---|---|---|
Immunomodulators | ||||
Corticosteroids | 1048 (73.1) | 354 (83.1%) | 694 (66.5%) | ≥ 0.001 |
Interferon | 152 (10.8) | 55 (12.9%) | 97 (9.3%) | 0.001** |
Convalescent plasma | 53 (3.8) | 46 (10.8%) | 7 (0.7%) | ≥ 0.0001 |
IVIG, Den | 51 (3.6) | 12 (2.8%) | 39 (3.7%) | 0.001** |
Plasmapheresis | 26 (1.8) | 4 (0.9%) | 22 (2.1%) | ≥ 0.0001 |
Antiviral medication | ||||
Chloroquine | 429 (30.5) | 141 (33.1%) | 288 (27.6%) | 0.001** |
Favipiravir | 316 (22.4) | 164 (38.5%) | 152 (14.6%) | ≥ 0.0001 |
Ribavirin | 241 (17.2) | 81 (19%) | 160 (15.3%) | 0.001 |
Remdesivir | 13 (0.9) | 6 (1.4%) | 7 (0.7%) | 0.001 |
Respiratory support during ICU admission | ||||
HFNC | 446 (30.3%) | 258 (60.6%) | 188 (18.0%) | 0.000*** |
BIPAP in ICU | 205 (13.9%) | 107 (25.1%) | 98 (9.4%) | 0.000*** |
Invasive mechanical ventilation (Intubation) | 778 (52.9%) | 216 (50.7%) | 562 (53.8%) | 0.276 |
ECMO | 71 (4.8%) | 28 (6.6%) | 43 (4.1%) | 0.046** |
